Literature DB >> 23949911

PulmoBind, an adrenomedullin-based molecular lung imaging tool.

Myriam Létourneau1, Quang Trinh Nguyen, François Harel, Alain Fournier, Jocelyn Dupuis.   

Abstract

UNLABELLED: Previous studies showed that adrenomedullin (AM) could be a promising agent for molecular imaging of the pulmonary circulation, with abundant specific binding sites at the pulmonary vascular endothelium. The purpose of this work was to design an AM-based compound that encompasses the desired imaging properties without posing safety issues for clinical applications.
METHODS: AM analogs were synthesized through solid-phase peptide synthesis. They were evaluated for (99m)Tc labeling efficiency and in vivo lung uptake. Biodistribution and hemodynamic characteristics of the lead compound were determined in anesthetized dogs as well as by a dosimetric analysis. Lung perfusion was evaluated in the monocrotaline model of pulmonary arterial hypertension in rats.
RESULTS: A cyclic AM (residues 22-52) analog encompassing a polyethylene glycol spacer and a tetrapeptide chelating moiety was found to possess the desired characteristics, with 90.7% ± 0.3% (mean ± SD) labeling efficiency, 40% lung uptake at 10 min after injection, and a favorable safety profile. Lung uptake of the (99m)Tc-labeled compound was markedly reduced in rats with pulmonary arterial hypertension.
CONCLUSION: This lead compound could be a suitable clinical imaging agent for the molecular diagnosis of disorders of the pulmonary circulation.

Entities:  

Keywords:  adrenomedullin; lung; molecular imaging; nuclear medicine; pulmonary hypertension

Mesh:

Substances:

Year:  2013        PMID: 23949911     DOI: 10.2967/jnumed.112.118984

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

Review 1.  SPECT and PET imaging of adrenomedullin receptors: a promising strategy for studying pulmonary vascular diseases.

Authors:  Luis Michel Alonso Martinez; François Harel; Myriam Létourneau; Vincent Finnerty; Alain Fournier; Jocelyn Dupuis; Jean N DaSilva
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

2.  Room With a View.

Authors:  Lai-Ming Yung; Paul B Yu
Journal:  Circ Cardiovasc Imaging       Date:  2018-08       Impact factor: 7.792

Review 3.  Molecular imaging of the pulmonary circulation in health and disease.

Authors:  Jocelyn Dupuis; François Harel; Quang T Nguyen
Journal:  Clin Transl Imaging       Date:  2014-09-09

4.  Evaluation of pulmonary perfusion by SPECT imaging using an endothelial cell tracer in supine humans and dogs.

Authors:  Xavier Levac; François Harel; Vincent Finnerty; Quang T Nguyen; Myriam Letourneau; Sophie Marcil; Alain Fournier; Jocelyn Dupuis
Journal:  EJNMMI Res       Date:  2016-05-27       Impact factor: 3.138

5.  Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial.

Authors:  François Harel; David Langleben; Steve Provencher; Alain Fournier; Vincent Finnerty; Quang T Nguyen; Myriam Letourneau; Xavier Levac; Gad Abikhzer; Jean Guimond; Asmaa Mansour; Marie-Claude Guertin; Jocelyn Dupuis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-24       Impact factor: 9.236

6.  PulmoBind Imaging Measures Reduction of Vascular Adrenomedullin Receptor Activity with Lack of effect of Sildenafil in Pulmonary Hypertension.

Authors:  Nassiba Merabet; Mohamed Jalloul Nsaibia; Quang Trinh Nguyen; Yan Fen Shi; Myriam Letourneau; Alain Fournier; Jean-Claude Tardif; François Harel; Jocelyn Dupuis
Journal:  Sci Rep       Date:  2019-04-29       Impact factor: 4.379

7.  SPECT imaging of pulmonary vascular disease in bleomycin-induced lung fibrosis using a vascular endothelium tracer.

Authors:  François Harel; Quang T Nguyen; Mohamed J Nsaibia; Vincent Finnerty; Arielle Morgan; Martin Sirois; Louis Villeneuve; Angelino Calderone; Alexandre Bergeron; Emmanuelle Brochiero; Jean-Claude Tardif; YanFen Shi; Jocelyn Dupuis
Journal:  Respir Res       Date:  2021-09-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.